The Effect of Soluble Epoxide Hydrolase (SEH) on Depression (NCT05575713) | Clinical Trial Compass
CompletedNot Applicable
The Effect of Soluble Epoxide Hydrolase (SEH) on Depression
China330 participantsStarted 2019-06-01
Plain-language summary
Depression is the most common mental disease and the second leading cause of chronic disease burden, which is closely related to suicidal behavior. The diagnosis and treatment of depression still lack of effective biological indicators, and about 30% of patients with depression still can not relieve their depressive symptoms after treatment. Previous studies have found that ATP release from astrocytes plays an important role in the occurrence, development and treatment of depression. Epoxy eicosotrienes (eets) are closely related to the function of the nervous system and may be the pathophysiological mechanism of depression. Soluble epoxide hydrolase (SEH) can regulate ATP release by affecting EET degradation, leading to depression like behavior and antidepressant effect, and sEH is closely related to cognitive function of depression.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Voluntarily sign informed consent;
✓. Age: 18-65 years old;
✓. Elementary school or above, able to understand and complete all inspections and assessments;
✓. Did not take any psychotropic drugs (including benzodiazepines) within 2 weeks before enrollment;
✓. After routine medical diagnosis by clinicians, they were divided into depression and healthy people.
Exclusion criteria
✕. Severe somatic or neurological diseases;
✕. Mental retardation and dementia;
✕. During pregnancy or breastfeeding;
✕. Heavy smoking, alcoholism and other substance abuse or dependence (within 3 months before enrollment);
✕. Electric shock treatment (within 3 months before enrollment);
What they're measuring
1
Change in Hamilton Depression Scale (HAMD-24)
Timeframe: Baseline, the second week, the first month, the second month, the third month, the sixth month and the first year
Trial details
NCT IDNCT05575713
SponsorNanfang Hospital, Southern Medical University